- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- AJANTA PHARMA - SHASUN PHARMA
AJANTA PHARMA vs SHASUN PHARMA - Comparison Results
Current Valuations
| AJANTA PHARMA | SHASUN PHARMA | AJANTA PHARMA/ SHASUN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 20.0 | 123.9 | 16.1% | View Chart |
| P/BV | x | 4.6 | 8.5 | 54.2% | View Chart |
| Dividend Yield | % | 0.0 | 0.2 | - |
Financials
 AJANTA PHARMA  SHASUN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AJANTA PHARMA Mar-18 |
SHASUN PHARMA Mar-14 |
AJANTA PHARMA/ SHASUN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,818 | 94 | 1,929.9% | |
| Low | Rs | 1,106 | 46 | 2,425.4% | |
| Sales per share (Unadj.) | Rs | 239.5 | 214.2 | 111.8% | |
| Earnings per share (Unadj.) | Rs | 52.8 | 5.3 | 989.4% | |
| Cash flow per share (Unadj.) | Rs | 59.5 | 15.8 | 376.1% | |
| Dividends per share (Unadj.) | Rs | 0 | 1.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.4 | 0.0% | |
| Book value per share (Unadj.) | Rs | 230.0 | 53.3 | 431.1% | |
| Shares outstanding (eoy) | m | 88.77 | 56.62 | 156.8% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 6.1 | 0.3 | 1,870.7% | |
| Avg P/E ratio | x | 27.7 | 13.1 | 211.4% | |
| P/CF ratio (eoy) | x | 24.6 | 4.4 | 556.1% | |
| Price / Book Value ratio | x | 6.4 | 1.3 | 485.2% | |
| Dividend payout | % | 0 | 18.7 | 0.0% | |
| Avg Mkt Cap | Rs m | 129,782 | 3,958 | 3,279.2% | |
| No. of employees | `000 | 6.8 | NA | - | |
| Total wages/salary | Rs m | 3,765 | 2,164 | 174.0% | |
| Avg. sales/employee | Rs Th | 3,128.4 | NM | - | |
| Avg. wages/employee | Rs Th | 554.0 | NM | - | |
| Avg. net profit/employee | Rs Th | 689.7 | NM | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 21,258 | 12,127 | 175.3% | |
| Other income | Rs m | 242 | 229 | 105.3% | |
| Total revenues | Rs m | 21,499 | 12,356 | 174.0% | |
| Gross profit | Rs m | 6,584 | 1,009 | 652.5% | |
| Depreciation | Rs m | 596 | 594 | 100.4% | |
| Interest | Rs m | 4 | 415 | 1.0% | |
| Profit before tax | Rs m | 6,226 | 230 | 2,710.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,539 | -73 | -2,116.5% | |
| Profit after tax | Rs m | 4,686 | 302 | 1,551.2% | |
| Gross profit margin | % | 31.0 | 8.3 | 372.2% | |
| Effective tax rate | % | 24.7 | -31.7 | -78.1% | |
| Net profit margin | % | 22.0 | 2.5 | 884.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 12,236 | 6,884 | 177.7% | |
| Current liabilities | Rs m | 3,461 | 8,456 | 40.9% | |
| Net working cap to sales | % | 41.3 | -13.0 | -318.5% | |
| Current ratio | x | 3.5 | 0.8 | 434.3% | |
| Inventory Days | Days | 60 | 62 | 97.7% | |
| Debtors Days | Days | 84 | 108 | 78.6% | |
| Net fixed assets | Rs m | 11,140 | 4,970 | 224.1% | |
| Share capital | Rs m | 177 | 113 | 156.1% | |
| "Free" reserves | Rs m | 20,237 | 2,875 | 703.9% | |
| Net worth | Rs m | 20,414 | 3,020 | 675.9% | |
| Long term debt | Rs m | 10 | 1,817 | 0.6% | |
| Total assets | Rs m | 24,486 | 13,347 | 183.5% | |
| Interest coverage | x | 1,519.4 | 1.6 | 97,814.7% | |
| Debt to equity ratio | x | 0 | 0.6 | 0.1% | |
| Sales to assets ratio | x | 0.9 | 0.9 | 95.6% | |
| Return on assets | % | 19.2 | 5.4 | 356.5% | |
| Return on equity | % | 23.0 | 10.0 | 229.5% | |
| Return on capital | % | 30.5 | 13.3 | 228.9% | |
| Exports to sales | % | 0 | 46.4 | 0.0% | |
| Imports to sales | % | 0 | 14.2 | 0.0% | |
| Exports (fob) | Rs m | NA | 5,622 | 0.0% | |
| Imports (cif) | Rs m | NA | 1,728 | 0.0% | |
| Fx inflow | Rs m | 11,667 | 5,843 | 199.7% | |
| Fx outflow | Rs m | 1,616 | 2,173 | 74.3% | |
| Net fx | Rs m | 10,052 | 3,669 | 273.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,854 | 398 | 717.9% | |
| From Investments | Rs m | -2,604 | -1,635 | 159.3% | |
| From Financial Activity | Rs m | -2 | 1,309 | -0.2% | |
| Net Cashflow | Rs m | 248 | 71 | 348.5% | |
Share Holding
| Indian Promoters | % | 73.8 | 39.2 | 188.3% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 1.6 | 3.6 | 43.1% | |
| FIIs | % | 7.6 | 17.6 | 43.2% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.0 | 39.6 | 42.9% | |
| Shareholders | 20,968 | 20,750 | 101.1% | ||
| Pledged promoter(s) holding | % | 4.4 | 12.3 | 35.7% |
Compare AJANTA PHARMA With: FDC LTD. UNICHEM LAB WYETH LTD DIVIS LABORATORIES FULFORD INDIA
Compare AJANTA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)
After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.
Related Views on News
AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)
Aug 1, 2018 | Updated on Aug 1, 2018For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)
Oct 31, 2018The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.
These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)
Nov 9, 2018All blue chip companies are large caps but all large caps are not blue chips.
Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)
Nov 2, 2018We believe insider buying is one of the strongest smart money indicators.
Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)
Nov 1, 2018PersonalFN explains the importance of being prepared for your child's future.
Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)
Nov 2, 2018PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.
More|
| |
AJANTA PHARMA SHARE PRICE
Nov 13, 2018 (Close)
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 8-QTR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.